Division of Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, United State of America.
Division of General Medical Sciences, Bioethics Research Center, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
PLoS One. 2022 Mar 24;17(3):e0265252. doi: 10.1371/journal.pone.0265252. eCollection 2022.
SARS-CoV-2 (COVID-19) has caused death and economic injury around the globe. The urgent need for COVID-19 research created new ethical, regulatory, and practical challenges. The next public health emergency could be worse than COVID-19. We must learn about these challenges from the experiences of researchers and Research Ethics Committee professionals responsible for these COVID-19 studies to prepare for the next emergency.
We conducted an online survey to identify the ethical, oversight, and regulatory challenges of conducting COVID-19 research during the early pandemic, and proposed solutions for overcoming these barriers. Using criterion-based, convenience sampling, we invited researchers who proposed or conducted COVID-19 research to complete an anonymous, online survey about their experiences. We administered a separate but related survey to Institutional Review Board (IRB) professionals who reviewed COVID-19 research studies. The surveys included open-ended and demographic items. We performed inductive content analysis on responses to open-ended survey questions.
IRB professionals (n = 143) and researchers (n = 211) described 19 types of barriers to COVID-19 research, related to 5 overarching categories: policy and regulatory, biases and misperceptions, institutional and inter-institutional conflicts, risks of harm, and pressure of the pandemic. Researchers and IRB professionals described 8 categories of adaptations and solutions to these challenges: enacting technological solutions; developing protocol-based solutions; disposition and team management; establishing and communicating appropriate standards; national guidance and leadership; maintaining high standards; prioritizing studies before IRB review; and identifying and incorporating experts.
This inventory of challenges represents ongoing barriers to studying the current pandemic, and they represent a risk to research during future public health emergencies. Delays in studies of a pandemic during a pandemic threatens the health and safety of the public. We urge the development of a national working group to address these issues before the next public health emergency arises.
SARS-CoV-2(COVID-19)在全球范围内造成了死亡和经济损失。对 COVID-19 研究的迫切需求带来了新的伦理、监管和实际挑战。下一次公共卫生紧急情况可能比 COVID-19 更糟。我们必须从负责这些 COVID-19 研究的研究人员和研究伦理委员会专业人员的经验中吸取这些挑战的教训,为下一次紧急情况做好准备。
我们进行了一项在线调查,以确定在大流行早期进行 COVID-19 研究的伦理、监督和监管挑战,并提出了克服这些障碍的解决方案。我们使用基于标准的便利抽样,邀请提出或进行 COVID-19 研究的研究人员完成一项关于他们经验的匿名在线调查。我们向审查 COVID-19 研究的机构审查委员会(IRB)专业人员进行了一项单独但相关的调查。调查包括开放式和人口统计学项目。我们对开放式调查问题的回答进行了归纳内容分析。
IRB 专业人员(n=143)和研究人员(n=211)描述了 COVID-19 研究的 19 种障碍,涉及 5 个总体类别:政策和监管、偏见和误解、机构和机构间冲突、伤害风险和大流行压力。研究人员和 IRB 专业人员描述了对这些挑战的 8 种适应和解决方案类别:实施技术解决方案;制定基于方案的解决方案;处置和团队管理;建立和沟通适当的标准;国家指导和领导;保持高标准;在 IRB 审查之前优先考虑研究;以及识别和纳入专家。
本清单代表了当前大流行研究的持续障碍,这对未来公共卫生紧急情况期间的研究构成了风险。在大流行期间延迟对大流行的研究威胁着公众的健康和安全。我们敦促在下次公共卫生紧急情况发生之前成立一个国家工作组来解决这些问题。